Cargando…
In Vivo Efficacy and Safety Evaluations of Therapeutic Splicing Correction Using U1 snRNA in the Mouse Retina
Efficacy and safety considerations constitute essential steps during development of in vivo gene therapies. Herein, we evaluated efficacy and safety of splice factor-based treatments to correct mutation-induced splice defects in an Opa1 mutant mouse line. We applied adeno-associated viruses to the r...
Autores principales: | Swirski, Sebastian, May, Oliver, Ahlers, Malte, Wissinger, Bernd, Greschner, Martin, Jüschke, Christoph, Neidhardt, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047704/ https://www.ncbi.nlm.nih.gov/pubmed/36980294 http://dx.doi.org/10.3390/cells12060955 |
Ejemplares similares
-
Autosomal dominant optic atrophy: A novel treatment for OPA1 splice defects using U1 snRNA adaption
por: Jüschke, Christoph, et al.
Publicado: (2021) -
Combining Engineered U1 snRNA and Antisense Oligonucleotides to Improve the Treatment of a BBS1 Splice Site Mutation
por: Breuel, Saskia, et al.
Publicado: (2019) -
U5 snRNA Interactions With Exons Ensure Splicing Precision
por: Artemyeva-Isman, Olga V., et al.
Publicado: (2021) -
Incorporation of 5-fluorouracil into U2 snRNA blocks pseudouridylation and pre-mRNA splicing in vivo
por: Zhao, Xinliang, et al.
Publicado: (2007) -
Recognition of atypical 5' splice sites by shifted base-pairing to U1 snRNA
por: Roca, Xavier, et al.
Publicado: (2009)